Management

Prof. Dario Neri
CEO & CSO
Co-founder

Dario Neri, Ph.D

Chief Executive Officer & Chief Scientific Officer
Co-founder

Dario Neri is Co-founder, CEO, CSO and President of the Scientific Advisory Board of Philogen. He graduated in Chemistry at the Scuola Normale Superiore in Pisa and obtained his Ph.D. in Chemistry from ETH Zurich, under the supervision of Prof. Kurt Wüthrich, winner of the Nobel Prize for Chemistry in 2002. For his dissertation, he was awarded the Silver Medal of ETH. After a 5 years post-doctoral research position in the lab of 2018 Chemistry Nobel Price Winner Sir Gregory Winter at the Cambridge Centre of Protein Engineering in Cambridge, UK, he returned to ETH Zurich in 1996 as Assistant Professor in Molecular Structure Biology. From 1999 he has been a Professor of Biomacromolecules in the Department of Chemistry and Applied Biosciences at ETH Zurich. He permanently joined Philogen in 2020, while retaining the Professor title of ETH Zürich. He is also a Honorary Senior Visiting Fellow of the University of Cambridge.

Prof. Neri is recipient of numerous awards, including the ISOBM Abbott Prize 2000, of the Amgen-Dompe' Biotec Award 2000, the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Phoenix Prize 2014 and of the Paul Harris Award 2022. He is author of more than 400 publications in international scientific journals.

Duccio Neri
Executive Chairman
Co-founder

Duccio Neri

Executive Chairman
Co-founder

Duccio Neri is Co-founder and Chairman of Philogen. He graduated in Business Administration and Economics at the Bocconi University in Milan, specializing in Corporate Finance. Dr. Neri has a special expertise in Financial Consulting, Tax and Audit Advice and Business Administration and is a Partner of the “Studio Neri – Tanini”. He was a representative of the Italian Government in the Board of the University of Siena and an auditor of the Cassa di Risparmio di San Miniato (CRSM) S.p.A., MPS Banca Verde S.p.A., MPS Fiduciaria S.p.A., MPS Professional S.p.A., and of several other firms.

Giovanni Neri, Ph.D.
Head of Licensing & IP
Co-founder

Giovanni Neri, Ph.D.

Head of Licensing & IP
Co-founder

Giovanni Neri is Co-founder and Director of IP & Licensing at Philogen S.p.A. Dr. Neri graduated in Biology at the University of Siena where he also received his doctorate in Biotechnology. He later specialized in antibody therapeutics in clinical oncology at the Royal Postgraduate Medical School at the Hammersmith Hospital, London from 1993 to 1995. At Philogen, he is responsible for developing the company's patent portfolio and is involved in the conclusion of all the major contractual agreements.

Laura Baldi
CFO

 

Laura Baldi

Chief Financial Officer

Laura Baldi graduated from the University of Siena in Economic and Banking Sciences. She was group controller at the general management of ENEL S.p.A. from 1997 to 1999. Mrs. Baldi has worked as a freelance consultant in management and tax matters for several corporations and she is a chartered accountant and auditor. Since 2003 Laura Baldi has worked for Philogen with increasing roles and responsibilities in the AFC area. She is currently Chief Financial Officer of the group and has more than ten years of experience in corporate secretariat functions.

Alfredo Covelli, MD

Chief Medical Officer

Alfredo Covelli was trained as a medical oncologist at the Department of Neoplastic Disease, Mount Sinai Hospital, New York. Before joining the pharma industry, he held academic positions at the Institute of Medical Pathology, School of Medicine in Naples and at the Division of Hematology, School of Medicine in Rome. Over the last 30 years, Dr. Covelli held a variety of Global and Country Management positions in the pharma industry, both in Clinical Research and in Commercial Operations in Italy, France, Switzerland and the United States (Farmitalia, Pierre Fabre, Sandoz, and Aventis). Before joining Philogen as Chief Medical officer, he served as Vice President and Head of Clinical Research and Medical Affairs for Europe at Novartis Oncology.

Dr. Covelli is also serving as a member of the Scientific Advisory Board to various Biotech Companies developing innovative therapies in oncology.

Alfredo Covelli, MD
CMO

Kevin Thomas

Legal Counsel

Kevin graduated with a degree in Law from Santa Clara University and a degree in Business Administration from San Jose State University. He has been a licensed attorney (California) since 2004. After working for a litigation practice in California, he began collaborating with JMU Law Firm in Florence. He worked for Philogen as an outside Counsel from 2006 to 2009 and has joined Philogen as in-house Counsel in 2009.

Kevin Thomas
Legal Counsel

Patrizia Sacchi

Legal Counsel

Patrizia graduated with a degree in Law from the University of Siena and obtained an LLM in European and Comparative Law from the University of Oxford. After her admission to the Italian bar, she worked for the Carnelutti law firm before joining Freshfields Bruckhaus Deringer, where she focused on M&A and corporate law.

Patrizia worked as Legal Counsel for Targetti Sankey S.p.A. and then for Novartis Vaccines and GSK Vaccines, consolidating her expertise in pharmaceutical companies, before joining Philogen in 2016, where she is currently responsible for the legal department.

Patrizia Sacchi
Legal Counsel

Katia Lorizzo

Deputy CMO and Head of Clinical Operations

Katia Lorizzo was trained as a medical oncologist at the European Institute of Oncology in Milan. She was also granted a PhD in Human Oncology at the University of Turin. Before joining the pharma industry, she worked for 11 years as medical assistant in the GI & NET department at the European Institute of Oncology in Milan, where she gained a lot of expertise in leading innovative clinical trials from FIH to PhIII.
Over the last 10 years, Dr. Lorizzo held different Regional and Country Management positions in the pharma industry, both in Clinical Research and Medical Affairs in Novartis and MSD.
Before joining Philogen as Head of Clinical Operations and Deputy Chief Medical officer, she served as Breast Cancer and Translational Clinical Oncology (TCO) Head At Novartis Oncology Italy.

Katia Lorizzo
Deputy CMO and Head of Clinical Operations